FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4289205101> ?p ?o ?g. }

• W4289205101 endingPage "1585" @default.
• W4289205101 startingPage "1585" @default.
• W4289205101 abstract "Objectives: The objective of this study was to explore the relationship between pharmacokinetic/pharmacodynamic (PK/PD) target attainment of continuous-infusion (CI) meropenem and microbiological outcome in critical COVID-19 patients with documented Gram-negative superinfections. Methods: Patients receiving CI meropenem for documented Gram-negative infections at the COVID ICU of the IRCCS Azienda Ospedaliero-Universitaria di Bologna and undergoing therapeutic drug monitoring from January 2021 to February 2022 were retrospectively assessed. Average steady-state meropenem concentrations (Css) were calculated and the Css/MIC ratio was selected as a pharmacodynamic parameter of meropenem efficacy. The Css/MIC ratio was defined as optimal if ≥4, quasi-optimal if between 1 and 4, and suboptimal if <1. The relationship between Css/MIC and microbiological outcome was assessed. Results: Overall, 43 critical COVID-19 patients with documented Gram-negative infections were retrieved. Combination therapy was implemented in 26 cases. Css/MIC ratios were optimal in 27 (62.8%), quasi-optimal in 7 (16.3%), and suboptimal in 9 cases (20.9%). Microbiological failure occurred in 21 patients (48.8%), with no difference between monotherapy and combination therapy (43.8% vs. 53.8%; p = 0.53). The microbiological failure rate was significantly lower in patients with an optimal Css/MIC ratio compared to those with a quasi-optimal or suboptimal Css/MIC ratio (33.3% vs. 75.0%; p = 0.01). Conclusion: Suboptimal attainment of meropenem PK/PD targets may be a major determinant impacting on microbiological failure in critical COVID-19 patients with Gram-negative superinfections." @default.
• W4289205101 created "2022-08-01" @default.
• W4289205101 creator A5005390430 @default.
• W4289205101 creator A5005906492 @default.
• W4289205101 creator A5029373468 @default.
• W4289205101 creator A5029747971 @default.
• W4289205101 creator A5037784764 @default.
• W4289205101 creator A5040568455 @default.
• W4289205101 creator A5045135007 @default.
• W4289205101 creator A5048760643 @default.
• W4289205101 creator A5050576915 @default.
• W4289205101 creator A5071687756 @default.
• W4289205101 date "2022-07-29" @default.
• W4289205101 modified "2023-10-17" @default.
• W4289205101 title "Relationship between Pharmacokinetic/Pharmacodynamic Target Attainment and Microbiological Outcome in Critically Ill COVID-19 Patients with Documented Gram-Negative Superinfections Treated with TDM-Guided Continuous-Infusion Meropenem" @default.
• W4289205101 cites W2017947220 @default.
• W4289205101 cites W2018554274 @default.
• W4289205101 cites W2031859080 @default.
• W4289205101 cites W2045006060 @default.
• W4289205101 cites W2093073135 @default.
• W4289205101 cites W2117538827 @default.
• W4289205101 cites W2128169890 @default.
• W4289205101 cites W2142343447 @default.
• W4289205101 cites W2149088130 @default.
• W4289205101 cites W2152344036 @default.
• W4289205101 cites W2156446002 @default.
• W4289205101 cites W2298261704 @default.
• W4289205101 cites W2766636752 @default.
• W4289205101 cites W2786886659 @default.
• W4289205101 cites W2792380978 @default.
• W4289205101 cites W2807199222 @default.
• W4289205101 cites W2809930572 @default.
• W4289205101 cites W2883234304 @default.
• W4289205101 cites W2892368225 @default.
• W4289205101 cites W2892490545 @default.
• W4289205101 cites W2922853445 @default.
• W4289205101 cites W2929478224 @default.
• W4289205101 cites W2963222371 @default.
• W4289205101 cites W3009885589 @default.
• W4289205101 cites W3011658165 @default.
• W4289205101 cites W3022327571 @default.
• W4289205101 cites W3093693178 @default.
• W4289205101 cites W3115438532 @default.
• W4289205101 cites W3115541698 @default.
• W4289205101 cites W3127311054 @default.
• W4289205101 cites W3197836442 @default.
• W4289205101 cites W3209839356 @default.
• W4289205101 cites W3210551305 @default.
• W4289205101 cites W4200573810 @default.
• W4289205101 cites W4211113261 @default.
• W4289205101 cites W4214735255 @default.
• W4289205101 cites W4226198795 @default.
• W4289205101 doi "https://doi.org/10.3390/pharmaceutics14081585" @default.
• W4289205101 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36015211" @default.
• W4289205101 hasPublicationYear "2022" @default.
• W4289205101 type Work @default.
• W4289205101 citedByCount "8" @default.
• W4289205101 countsByYear W42892051012022 @default.
• W4289205101 countsByYear W42892051012023 @default.
• W4289205101 crossrefType "journal-article" @default.
• W4289205101 hasAuthorship W4289205101A5005390430 @default.
• W4289205101 hasAuthorship W4289205101A5005906492 @default.
• W4289205101 hasAuthorship W4289205101A5029373468 @default.
• W4289205101 hasAuthorship W4289205101A5029747971 @default.
• W4289205101 hasAuthorship W4289205101A5037784764 @default.
• W4289205101 hasAuthorship W4289205101A5040568455 @default.
• W4289205101 hasAuthorship W4289205101A5045135007 @default.
• W4289205101 hasAuthorship W4289205101A5048760643 @default.
• W4289205101 hasAuthorship W4289205101A5050576915 @default.
• W4289205101 hasAuthorship W4289205101A5071687756 @default.
• W4289205101 hasBestOaLocation W42892051011 @default.
• W4289205101 hasConcept C111113717 @default.
• W4289205101 hasConcept C112705442 @default.
• W4289205101 hasConcept C126322002 @default.
• W4289205101 hasConcept C176947019 @default.
• W4289205101 hasConcept C2779134260 @default.
• W4289205101 hasConcept C2779375183 @default.
• W4289205101 hasConcept C3008058167 @default.
• W4289205101 hasConcept C501593827 @default.
• W4289205101 hasConcept C524204448 @default.
• W4289205101 hasConcept C71924100 @default.
• W4289205101 hasConcept C86803240 @default.
• W4289205101 hasConcept C89423630 @default.
• W4289205101 hasConcept C94665300 @default.
• W4289205101 hasConceptScore W4289205101C111113717 @default.
• W4289205101 hasConceptScore W4289205101C112705442 @default.
• W4289205101 hasConceptScore W4289205101C126322002 @default.
• W4289205101 hasConceptScore W4289205101C176947019 @default.
• W4289205101 hasConceptScore W4289205101C2779134260 @default.
• W4289205101 hasConceptScore W4289205101C2779375183 @default.
• W4289205101 hasConceptScore W4289205101C3008058167 @default.
• W4289205101 hasConceptScore W4289205101C501593827 @default.
• W4289205101 hasConceptScore W4289205101C524204448 @default.
• W4289205101 hasConceptScore W4289205101C71924100 @default.
• W4289205101 hasConceptScore W4289205101C86803240 @default.
• W4289205101 hasConceptScore W4289205101C89423630 @default.
• W4289205101 hasConceptScore W4289205101C94665300 @default.
• W4289205101 hasIssue "8" @default.

• next